特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
932835

獣医腫瘍学の世界市場: 市場規模、シェア、動向分析 - 治療法、動物の種類、癌の種類、地域別

Veterinary Oncology Market Size, Share & Trends Analysis Report By Therapy, By Animal Type, By Cancer Type, By Region, And Segment Forecasts, 2020 - 2027

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 120 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.56円
獣医腫瘍学の世界市場: 市場規模、シェア、動向分析 - 治療法、動物の種類、癌の種類、地域別
出版日: 2020年04月01日
発行: Grand View Research, Inc.
ページ情報: 英文 120 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

獣医腫瘍学の世界市場規模は、2020年から2027年にかけて10.7%のCAGRで推移し、市場規模は2027年までに4億4,700万米ドルに達すると予測されています。ペットの癌有病率の増加と獣医診断の需要は予測期間にわたって市場の成長を促進すると期待されます。

当レポートでは、世界の獣医腫瘍学市場を調査し、市場の概要、技術・用途・治療方、動物、癌の種類・地域別の市場規模の推移と予測、市場シェア、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査手法と範囲

  • 市場区分と範囲
  • 調査手法
  • 情報調達
  • 情報分析
  • 市場形成と検証
  • モデル詳細
  • 二次情報源のリスト
  • 一次情報源のリスト
  • 略語
  • 目的

第2章 エグゼクティブサマリー

  • 市場の見通し
  • セグメント別の見通し
  • 競合考察

第3章 市場変数・傾向・範囲

  • 市場系統の見通し
  • 浸透と成長の見通しマッピング(技術別、2019 )
  • ユーザーの視点分析
  • 主要なエンドユーザーのリスト
  • 規制の枠組み
  • テクノロジーの概要
  • 市場力学
  • 業界分析-ポーター
  • SWOT分析、要因別(政治・法律、経済、社会、技術)
  • 主な取引と戦略的提携

第4章 競合分析

  • 市場参加分類
  • 競争分析

第5章 獣医腫瘍学世界市場:治療タイプ分析

  • 治療タイプビジネス分析

第6章 獣医腫瘍学世界市場:動物タイプ

  • 動物タイプ分析

第7章 獣医腫瘍学世界市場:癌タイプ

  • がんの種類ビジネス分析

第8章 獣医腫瘍学世界市場:地域別分析(治療法、動物の種類、がんの種類 2016年~2027年)

  • シェア分析、2019および2027
  • ダッシュボード
  • スナップショット
  • 市場規模、および予測とトレンド分析、2019年から2027年

第9章 企業プロファイル

  • Boehringer Ingelheim International GmbH
  • Elanco
  • Zoetis
  • PetCure Oncology
  • Accuray Incorporated
  • Varian Medical System, Inc.
  • Nippon Zenyaku Kogyo Co., Ltd.
  • Morphogenesis, Inc.
  • Karyopharm Therapeutics, Inc.,
  • Regeneus Ltd.
  • One Health
図表

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 List of abbreviation
  • TABLE 3 List of veterinary oncology service providers
  • TABLE 4 North America veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 5 North America veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 6 North America veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)
  • TABLE 7 U.S. veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 8 U.S. veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 9 U.S. veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)
  • TABLE 10 Canada veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 11 Canada veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 12 Canada veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)
  • TABLE 13 Europe veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 14 Europe veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 15 Europe veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)
  • TABLE 16 U.K. veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 17 U.K. veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 18 U.K. veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)
  • TABLE 19 Germany veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 20 Germany veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 21 Germany veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)
  • TABLE 22 Asia Pacific veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 23 Asia Pacific veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 24 Asia Pacific veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)
  • TABLE 25 Latin America veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 26 Latin America veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 27 Latin America veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)
  • TABLE 28 MEA veterinary oncology market, by Therapy, 2016 - 2027 (USD Million)
  • TABLE 29 MEA veterinary oncology market, by animal type, 2016 - 2027 (USD Million)
  • TABLE 30 MEA veterinary oncology market, by cancer type, 2016 - 2027 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Veterinary Oncology executive summary, 2019, (USD Million)
  • Fig. 11 Veterinary Oncology market revenues, 2019, (USD Million)
  • Fig. 12 Segment outlook
  • Fig. 13 Strategy framework
  • Fig. 14 Parent market outlook
  • Fig. 15 Ancillary market outlook
  • Fig. 16 Penetration &growth prospect mapping by technology, 2019
  • Fig. 17 Veterinary oncology trend analysis
  • Fig. 18 Veterinary oncology timeline analysis
  • Fig. 19 Market trends & outlook
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Market restraints relevance analysis (Current & future impact)
  • Fig. 22 Porter's five force model
  • Fig. 23 Veterinary Oncology - SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 24 Market participant categorization
  • Fig. 25 Veterinary oncology company market position analysis
  • Fig. 26 Veterinary oncology market Therapy outlook: Key takeaways
  • Fig. 27 Veterinary oncology market: Therapy type movement analysis
  • Fig. 28 Global ENT market, 2016 - 2027 (USD Million)
  • Fig. 29 Global radiology market, 2016 - 2027 (USD Million)
  • Fig. 30 Global chemotherapy market, 2016 - 2027 (USD Million)
  • Fig. 31 Global immunotherapy market, 2016 - 2027 (USD Million)
  • Fig. 32 Global others market, 2016 - 2027 (USD Million)
  • Fig. 33 Veterinary oncology market animal type outlook: Key takeaways
  • Fig. 34 Veterinary oncology market: Technology type movement analysis
  • Fig. 35 Global canine market, 2016 - 2027 (USD Million)
  • Fig. 36 Global feline market, 2016 - 2027 (USD Million)
  • Fig. 37 Veterinary oncology market cancer type outlook: Key takeaways
  • Fig. 38 Veterinary oncology market: Cancer type movement analysis
  • Fig. 39 Global lymphoma market, 2016 - 2027 (USD Million)
  • Fig. 40 Global mast cell cancer market, 2016 - 2027 (USD Million)
  • Fig. 41 Global mammary and squamous cell cancer market, 2016 - 2027 (USD Million)
  • Fig. 42 Global others market, 2016 - 2027 (USD Million)
  • Fig. 43 Regional outlook, 2019 & 2027
  • Fig. 44 Regional market dashboard
  • Fig. 45 Regional marketplace: Key takeaways
  • Fig. 46 North America veterinary oncology, 2016 - 2027 (USD Million)
  • Fig. 47 North America veterinary oncology market by countries, 2016 - 2027 (USD Million)
  • Fig. 48 U.S. veterinary oncology market, 2016 - 2027 (USD Million)
  • Fig. 49 Canada veterinary oncology market, 2016 - 2027 (USD Million)
  • Fig. 50 Europe veterinary oncology, 2016 - 2027 (USD Million)
  • Fig. 51 Europe veterinary oncology market by countries, 2016 - 2027 (USD Million)
  • Fig. 52 U.K. veterinary oncology, 2016 - 2027 (USD Million)
  • Fig. 53 Germany veterinary oncology market, 2016 - 2027 (USD Million)
  • Fig. 54 Asia Pacific veterinary oncology market, 2016 - 2027 (USD Million)
  • Fig. 55 Latin America veterinary oncology market, 2016 - 2027 (USD Million)
  • Fig. 56 MEA veterinary oncology market, 2016 - 2027 (USD Million)
目次
Product Code: GVR-4-68038-182-5

The global veterinary oncology market size is expected to reach USD 447.0 million by 2027, expanding at a CAGR of 10.7% over the forecast period, according to a new report by Grand View Research, Inc. Increasing prevalence of cancer in pets and demand for veterinary diagnostics are projected to drive the market over the forecast period.

Adoption of canine cancer registry globally to estimate cancer incidences is another driving factor for the market growth. According to frontiers in Veterinary Science in February 2019, the Swiss Canine Cancer Registry (SCCR) was used as a data source and was compiled for future comparative studies of canine and human cancers. This database is further helpful in mitigating the incidence of malignant tumors in the human population, thereby driving the market growth.

Researchers carrying out studies focused on veterinary oncology are further boosting the veterinary oncology market growth. For instance, University of Illinois in August 2017, carried out study that involves more precise detection of metastasis (spread of cancer through the body) for head and neck tumors in dogs. Moreover, the market players are also focusing on new product innovation and strategic collaborations. For instance, in 2018 AdvaVet, a subsidiary of Oasmia Pharmaceutical AB, developed XR17 technology, which is nanoparticle formulation based that makes a single Active Pharmaceutical Ingredient (API) or multiple APIs water soluble. It is a combination therapy and is also a standard treatment for a number of cancer diseases in pet animals.

Further key findings from the report suggest:

Increasing prevalence of cancer in animals, clinical trial studies to evaluate safety and effectiveness of cancer therapeutics, and technological advancements in veterinary oncology treatment are anticipated to create growth opportunities in the market

The chemotherapy segment is anticipated to account for the largest revenue share over the coming years owing to its increasing adoption either alone or in combination with other therapies

The canine segment held the largest revenue in 2019 owing to increasing population of dogs and high prevalence of cancer in dogs as compared to cats

Lymphoma dominated the market among other cancer types in 2019, due to high mortality rate in companion animals

North America held the dominant share of the veterinary oncology market in 2019, due to favorable government policies, new product launches, and huge investment in oncology treatment

Asia Pacific is anticipated to witness lucrative growth due to increasing focus on animal health and expenditure, increasing number of pets being exposed to cancer, and government focus on animal safety and initiatives to curb cancer in pet animals

Some of the key companies are Boehringer Ingelheim; PetCure Oncology; Elanco; Accuray Incorporated; Varian Medical Systems; Zoetis; Karyopharm Therapeutics, Inc.; One Health; and Regeneus Ltd.

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Segment Scope
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates & Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary Research:
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
  • 1.7 List of Secondary Sources
  • 1.8 List of Primary Sources
  • 1.9 Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1:
    • 1.10.2 Objective 2:
    • 1.10.3 Market Definitions

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Competitive Outlook

Chapter 3 Veterinary Oncology Market Variables Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
    • 3.1.2 Ancillary market outlook
  • 3.2 Penetration & Growth Prospect Mapping by Technology, 2019
  • 3.3 User Perspective Analysis
    • 3.3.1 Market influencer analysis
  • 3.4 List of Key End Users
  • 3.5 Regulatory Framework
    • 3.5.1 Regulatory Landscape
  • 3.6 Technology Overview
    • 3.6.1 Veterinary Oncology timeline analysis
  • 3.7 Market Dynamics
    • 3.7.1 Market Driver Analysis
      • 3.7.1.1 Upsurge in the prevalence of cancer in pet animals
      • 3.7.1.2 Increasing research and investments in pet cancer
      • 3.7.1.3 Growing focus on animal safety
      • 3.7.1.4 Technological advancements in pet cancer treatment
    • 3.7.2 Market Restraints Analysis
      • 3.7.2.1 High cost of pet cancer treatment
      • 3.7.2.2 Lack of awareness among pet owners about pet disease
      • 3.7.2.3 Adverse effects of drugs used for pet cancer treatment
  • 3.8 Industry Analysis - Porter's
    • 3.8.1 Supplier Power
    • 3.8.2 Buyer Power
    • 3.8.3 Threat of Substitutes
    • 3.8.4 Threat of New Entrants
    • 3.8.5 Competitive Rivalry
  • 3.9 Veterinary Oncology - SWOT Analysis, by Factor (Political & Legal, Economic, Social and Technological)
    • 3.9.1 Political Landscape
    • 3.9.2 Economic Landscape
    • 3.9.3 Technology Landscape
    • 3.9.4 Social Landscape
  • 3.10 Major Deals and Strategic alliances

Chapter 4 Veterinary Oncology Market: Competitive Analysis

  • 4.1 Market Participation Categorization
  • 4.2 Competitive Analysis
    • 4.2.1 Company market position analysis
    • 4.2.2 Market leader
    • 4.2.3 Innovators
    • 4.2.4 Vendor Landscape
      • 4.2.4.1 List of veterinary Oncology service providers

Chapter 5 Veterinary Oncology Market: Therapy type analysis

  • 5.1 Therapy Type Business Analysis
    • 5.1.1 Surgery
      • 5.1.1.1 Surgery market estimates and forecasts, 2016 - 2027 (USD Million)
    • 5.1.2 Radiology
      • 5.1.2.1 Radiology market estimates and forecasts, 2016 - 2027 (USD Million)
    • 5.1.3 Chemotherapy
      • 5.1.3.1 Chemotherapy market estimates and forecasts, 2016 - 2027 (USD Million)
    • 5.1.4 Immunotherapy
      • 5.1.4.1 Immunotherapy market estimates and forecasts, 2016 - 2027 (USD Million)
    • 5.1.5 Others
      • 5.1.5.1 Others market estimates and forecasts, 2016 - 2027 (USD Million)

Chapter 6 Veterinary Oncology Market: Animal Type

  • 6.1 Animal Type Analysis
    • 6.1.1 Canine
      • 6.1.1.1 Canine market estimates and forecasts, 2016 - 2027 (USD Million)
    • 6.1.2 Feline
      • 6.1.2.1 Feline market estimates and forecasts, 2016 - 2027 (USD Million)

Chapter 7 Veterinary Oncology Market: Cancer Type

  • 7.1 Cancer Type Business Analysis
    • 7.1.1 Lymphoma
      • 7.1.1.1 Lymphoma market estimates and forecasts, 2016 - 2027 (USD Million)
    • 7.1.2 Mast Cell Cancer
      • 7.1.2.1 Mast Cell Cancer market estimates and forecasts, 2016 - 2027 (USD Million)
    • 7.1.3 Mammary and Squamous Cell Cancer
      • 7.1.3.1 Mammary and Squamous Cell Cancer market estimates and forecasts, 2016 - 2027 (USD Million)
    • 7.1.4 Others
      • 7.1.4.1 Others market estimates and forecasts, 2016 - 2027 (USD Million)

Chapter 8 Veterinary Oncology: Regional Market Analysis, By Therapy, Animal type, and Cancer Type 2016 - 2027 (USD Million)

  • 8.1 Regional Market Share Analysis, 2019 & 2027
  • 8.2 Regional Market Dashboard
  • 8.3 Regional Market Snapshot
  • 8.4 Market Size, & Forecasts and Trend Analysis, 2019 to 2027
    • 8.4.1 North America
      • 8.4.1.1 Veterinary oncology market estimates and segment forecasts, 2016 - 2027 (USD Million)
      • 8.4.1.2 U.S.
      • 8.4.1.2.1 Veterinary oncology market estimates and forecasts, 2016 - 2027 (USD Million)
      • 8.4.1.3 Canada
      • 8.4.1.3.1 Veterinary oncology market estimates and forecasts, 2016 - 2027 (USD Million)
    • 8.4.2 Europe
      • 8.4.2.1 Veterinary oncology market estimates and forecasts by countries, 2016 - 2027 (USD Million)
      • 8.4.2.2 U.K.
      • 8.4.2.2.1 Veterinary oncology market estimates and forecasts, 2016 - 2027 (USD Million)
      • 8.4.2.3 Germany
      • 8.4.2.3.1 Veterinary oncology market estimates and forecasts, 2016 - 2027 (USD Million)
    • 8.4.3 Asia Pacific
      • 8.4.3.1 Veterinary oncology market estimates and forecasts, 2016 - 2027 (USD Million)
    • 8.4.4 Latin America
      • 8.4.4.1 Veterinary oncology market estimates and forecasts, 2016 - 2027 (USD Million)
    • 8.4.5 MEA
      • 8.4.5.1 Veterinary oncology market estimates and forecasts by countries, 2016 - 2027 (USD Million)

Chapter 9 Company Profiles

  • 9.1 Boehringer Ingelheim International GmbH
    • 9.1.1 Company Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Benchmarking
    • 9.1.4 Strategic Initiatives
  • 9.2 Elanco
    • 9.2.1 Company Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Benchmarking
    • 9.2.4 Strategic Initiatives
  • 9.3 Zoetis
    • 9.3.1 Company Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Benchmarking
    • 9.3.4 Strategic Initiatives
  • 9.4 PetCure Oncology
    • 9.4.1 Company Overview
    • 9.4.2 Product Benchmarking
    • 9.4.3 Strategic Initiatives
  • 9.5 Accuray Incorporated
    • 9.5.1 Company Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Benchmarking
    • 9.5.4 Strategic Initiatives
  • 9.6 Varian Medical System, Inc.
    • 9.6.1 Company Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Benchmarking
    • 9.6.4 Strategic Initiatives
  • 9.7 Nippon Zenyaku Kogyo Co., Ltd.
    • 9.7.1 Company Overview
    • 9.7.2 Product Benchmarking
    • 9.7.3 Strategic Initiatives
  • 9.8 Morphogenesis, Inc.
    • 9.8.1 Company Overview
    • 9.8.2 Product Benchmarking
    • 9.8.3 Strategic Initiatives
  • 9.9 Karyopharm Therapeutics, Inc.,
    • 9.9.1 Company Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Benchmarking
    • 9.9.4 Strategic Initiatives
  • 9.10 Regeneus Ltd.
    • 9.10.1 Company Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Benchmarking
    • 9.10.4 Strategic Initiatives
  • 9.11 One Health
    • 9.11.1 Company Overview
    • 9.11.2 Product Benchmarking
    • 9.11.3 Strategic Initiatives
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.